retatrutide ly3437943 triple agonist glp-1 gip glucagon Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% retatrutide ly3437943 glp-1 gip glucagon

Filed Under: Biologics, Endocrinology

Some Kaiser plans cover Mounjaro for diabetes management after other medications have failed

Staying well-hydrated helps your body digest food more easily and move it more swiftly through your digestive tract

Most experts agree that 0.5 to 2.0 pounds per week, or roughly 1% of body weight, is appropriate

Retatrutide is currently an investigational medication undergoing clinical trials, and regulatory approval status may vary by country

Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, not yet licensed by the MHRA or EMA, and currently in Phase 2 and Phase 3 clinical trials